Philadelphia, Pennsylvania
Cancer clinical trials in Philadelphia, PA
296 cancer studies are recruiting participants at sites in Philadelphia as of November 16, 2026, according to ClinicalTrials.gov. Oncology Research Hub can help you understand your options and connect with a study team.
- No cost to ask
- Taking part is voluntary
- Studies are independently reviewed
Philadelphia at a glance
- 296 studies are recruiting at a site in Philadelphia.
- By phase: Early Phase 1 (5), Phase 1 (50), Phase 1/2 (50), Phase 2 (48), Phase 2/3 (8), Phase 3 (65), Phase 4 (3), No phase (29), Observational (38). Studies of devices and behavioral approaches have no phase.
- By sponsor: industry (142), university, hospital or other (136), government (18).
- By research area: Lung Cancer (76), Lymphoma (72), Breast Cancer (70), Prostate Cancer (33), Pancreatic Cancer (23), Melanoma (22).
- Most recent update to one of these records: November 16, 2026.
Breast cancer studies recruiting in Philadelphia
Basic details from each study's public record (the 30 most recently updated of 296). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
- Phase 2
- All ages
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- Fox Chase Cancer Center · Pennsylvania Hospital · Thomas Jefferson University Hospital
- Registry record
- NCT05564377 · updated
S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer
- No phase
- Ages 18 and older
- All sexes
- Sponsor
- SWOG Cancer Research Network
- Study site
- Thomas Jefferson University Hospital
- Registry record
- NCT03723928 · updated
Source: ClinicalTrials.gov. Data processed . See every breast cancer study recruiting in Philadelphia, PA on ClinicalTrials.gov.
Lung cancer studies recruiting in Philadelphia
LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- NovoCure GmbH
- Study site
- Abramson Cancer Center
- Registry record
- NCT06216301 · updated
A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- IDEAYA Biosciences
- Study site
- Sidney Kimmel Comprehensive Cancer Center Thomas Jefferson University
- Registry record
- NCT07277413 · updated
A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- Perelman Center for Advanced Medicine ( Site 3205)
- Registry record
- NCT07513376 · updated
Pembrolizumab in Combination With Chemotherapy and Image-Guided Surgery for Malignant Pleural Mesothelioma (MPM)
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- Abramson Cancer Center at Penn Medicine
- Study site
- Abramson Cancer Center of the University of Pennsylvania
- Registry record
- NCT03760575 · updated
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- Fox Chase Cancer Center · Temple University Hospital · Thomas Jefferson University Hospital
- Registry record
- NCT04267848 · updated
Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- Fox Chase Cancer Center · Temple University Hospital
- Registry record
- NCT04665739 · updated
Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
- Phase 3
- Ages 70 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- ECOG-ACRIN Cancer Research Group
- Registry record
- NCT06096844 · updated
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- Jefferson Torresdale Hospital · Thomas Jefferson University Hospital
- Registry record
- NCT06498635 · updated
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-based Chemotherapy With or Without Amivantamab for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
- Phase 2/3
- Ages 18 and older
- All sexes
- Sponsor
- Bristol-Myers Squibb
- Study site
- Hospital of the University of Pennsylvania
- Registry record
- NCT07100080 · updated
A Phase 1 Dose Escalation and Dose Expansion Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- Kestrel Therapeutics, Inc.
- Study site
- Sidney Kimmel Cancer Center
- Registry record
- NCT07458347 · updated
RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses
- Phase 2
- Ages 18 to 80
- All sexes
- Sponsor
- Reunion Neuroscience Inc
- Study site
- University of Pennsylvania
- Registry record
- NCT07002034 · updated
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Verastem, Inc.
- Study site
- Univ of Pennsylvania, Abramson Cancer Center
- Registry record
- NCT07020221 · updated
Phase I/II Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marrow Transplantation for Hematologic Malignancies
- Phase 1/2
- Ages 12 to 85
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- Hospital of the University of Pennsylvania
- Registry record
- NCT04959175 · updated
Source: ClinicalTrials.gov. Data processed . See every lung cancer study recruiting in Philadelphia, PA on ClinicalTrials.gov.
Prostate cancer studies recruiting in Philadelphia
Carboplatin or Olaparib for BRcA Deficient Prostate Cancer
- Phase 2
- Ages 18 and older
- Male participants
- Sponsor
- VA Office of Research and Development
- Study site
- Philadelphia MultiService Center, Philadelphia, PA
- Registry record
- NCT04038502 · updated
Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
- Phase 3
- Ages 18 and older
- Male participants
- Sponsor
- ECOG-ACRIN Cancer Research Group
- Study sites
- Penn Presbyterian Medical Center · Thomas Jefferson University Hospital · University of Pennsylvania/Abramson Cancer Center
- Registry record
- NCT04423211 · updated
Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer
- Phase 1
- Ages 18 and older
- Male participants
- Sponsor
- Amgen
- Study site
- Thomas Jefferson University
- Registry record
- NCT04221542 · updated
Source: ClinicalTrials.gov. Data processed . See every prostate cancer study recruiting in Philadelphia, PA on ClinicalTrials.gov.
Melanoma studies recruiting in Philadelphia
Comparing the Effectiveness of Less Invasive Procedures With the Current Standard of Care for the Treatment of Older Adults With Early-Stage Melanoma
- Phase 3
- Ages 75 and older
- All sexes
- Sponsor
- ECOG-ACRIN Cancer Research Group
- Study sites
- Fox Chase Cancer Center · Thomas Jefferson University Hospital
- Registry record
- NCT07068074 · updated
Study of Adjuvant Darovasertib and Crizotinib in Participants With Primary Non-metastatic Uveal Melanoma
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- IDEAYA Biosciences
- Study site
- Wills Eye Hospital at Thomas Jefferson University
- Registry record
- NCT07804186 · updated
Source: ClinicalTrials.gov. Data processed . See every melanoma study recruiting in Philadelphia, PA on ClinicalTrials.gov.
Lymphoma studies recruiting in Philadelphia
A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)
- Phase 1
- Ages 0 to 18
- All sexes
- Sponsor
- Autolus Limited
- Study site
- Children's Hospital of Philadelphia
- Registry record
- NCT06173518 · updated
A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study sites
- Abramson Cancer Center and Perelman Center for Advanced Medicine ( Site 0131) · Temple University Hospital ( Site 0133)
- Registry record
- NCT06890884 · updated
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- Jefferson Torresdale Hospital · Thomas Jefferson University Hospital
- Registry record
- NCT04269902 · updated
A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
- Phase 2
- Ages 1 to 30
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- Children's Hospital of Philadelphia · Saint Christopher's Hospital for Children
- Registry record
- NCT04546399 · updated
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
- Phase 3
- Ages 5 to 60
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- Children's Hospital of Philadelphia · Saint Christopher's Hospital for Children · Thomas Jefferson University Hospital
- Registry record
- NCT05675410 · updated
Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- Fox Chase Cancer Center · Thomas Jefferson University Hospital
- Registry record
- NCT06337318 · updated
A Study of Fludarabine Dosing in Children and Young Adults With B-cell Acute Lymphoblastic Leukemia
- Phase 3
- Ages 1 and older
- All sexes
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Study site
- Children's Hospital of Philadelphia
- Registry record
- NCT07223021 · updated
Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- Thomas Jefferson University Hospital
- Registry record
- NCT06649812 · updated
Source: ClinicalTrials.gov. Data processed . See every lymphoma study recruiting in Philadelphia, PA on ClinicalTrials.gov.
Pancreatic cancer studies recruiting in Philadelphia
A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Incyte Corporation
- Study sites
- Investigative Site US008 · Investigative Site US043
- Registry record
- NCT07522073 · updated
APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- University of Pennsylvania/Abramson Cancer Center
- Registry record
- NCT04858334 · updated
Source: ClinicalTrials.gov. Data processed . See every pancreatic cancer study recruiting in Philadelphia, PA on ClinicalTrials.gov.
Ask about studies near Philadelphia
Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.
Before you contact a study
How taking part works
From your first question to your decision: what happens and who you talk to along the way.
Questions to ask a study team
What to ask about time, risks and your rights before you agree to anything.
Eligibility and screening
How a study team works out whether a study is suitable for you.
More locations in Pennsylvania
All Pennsylvania locations
503 studies recruiting across 87 cities.
Pittsburgh
217 studies recruiting.
About these listings
These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 16, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded.
Oncology Research Hub does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.
Sources and further reading
- ClinicalTrials.gov study registry — ClinicalTrials.gov (National Library of Medicine)
- Terms and Conditions for use of ClinicalTrials.gov data — ClinicalTrials.gov (National Library of Medicine)
- Questions to Ask About Volunteering for a Research Study — HHS Office for Human Research Protections